Table 4.
Results for clinical parameters.
| No. of patients | 2010–2012 | 2013–2015 | 2016–2017 | |
|---|---|---|---|---|
| Patients with immunomodulatory therapy (%) | 12,534 | 68.4 | 75.1 | 76.8 |
| Newly diagnosed patients with first therapy after ≤ 6 months (%) | 4,188 | 61.5 | 71.7 | 69.2 |
| Time from first symptom to initiation of immunomodulatory therapy (days) | 1,880 | 233.6 | 149.4 | 114.2 |
| Time from therapy initiation to discontinuation (months) | 7,291 | 22.8 | 13.6 | 6.0 |
| Annualized relapse rate (ARR) | 14,846 | 0.23 | 0.17 | 0.16 |
| Time to first relapse (days) | 4,143 | 322.0 | 495.6 | 720.2 |
| Time to confirmed EDSS progression with baseline EDSS <3 (months) | 161 | 130.7 | 131.6 | 169.8 |
| Time to confirmed EDSS progression with baseline EDSS <5 (months) | 53 | 193.4 | 182.3 | 243.4 |